EGFR and non-small cell lung carcinoma: The largest of these trials utilized ddPCR to analyze baseline and on-treatment samples from 489 patients in the FLAURA trial, a first-line trial of osimertinib versus comparator EGFR TKI in patients with EGFR mutant NSCLC.